Effect of hemodialysis before transplant surgery on renal allograft function-A pair of randomized controlled trials

Transplantation

Volumn 88, Issue 12, 2009, Pages 1377-1385

  Kikić, Zěljko ^a   Lorenz, Matthias ^b   Sunder Plassmann, Gere ^a   Schillinger, Martin ^a   Regele, Heinz ^a   Györi, Georg ^a   Mühlbacher, Ferdinand ^a   Winkelmayer, Wolfgang C ^c   Böhmig, Georg A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute renal failure; Citrate anticoagulation; Clinical trial; Delayed graft function; Hemodialysis; Kidney transplantation

Indexed keywords

CITRATE TRISODIUM; COMPLEMENT COMPONENT C4D; HEPARIN; POTASSIUM;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HEMODIALYSIS; HUMAN; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; PREOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ALLOTRANSPLANTATION; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; FOLLOW UP; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; TIME; TREATMENT OUTCOME;

ADULT; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 74049120075     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181bc03ab     Document Type: Article

References (43)

1. Ojo AO, Wolfe RA, Held PJ, et al. Delayed graft function: Risk factors and implications for renal allograft survival. Transplantation 1997; 63: 968.
2. Halloran PF, Hunsicker LG. Delayed graft function: State of the art, November 10-11, 2000. Summit meeting, Scottsdale, Arizona, USA. Am J Transplant 2001; 1: 115.
3. Perico N, Cattaneo D, Sayegh MH, et al. Delayed graft function in kidney transplantation. Lancet 2004; 364: 1814.
4. Yarlagadda SG, Klein CL, Jani A. Long-term renal outcomes after delayed graft function. Adv Chronic Kidney Dis 2008; 15: 248.
5. Sanfilippo F, Vaughn WK, Spees EK, et al. The detrimental effects of delayed graft function in cadaver donor renal transplantation. Transplantation 1984; 38: 643.
6. Boom H, Mallat MJ, de Fijter JW, et al. Delayed graft function influences renal function, but not survival. Kidney Int 2000; 58: 859.
7. Mikhalski D, Wissing KM, Ghisdal L, et al. Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression. Transplantation 2008; 85(7 suppl): S3.
8. Peeters P, Vanholder R. Therapeutic interventions favorably influencing delayed and slow graft function in kidney transplantation: Mission impossible? Transplantation 2008; 85(7 suppl): S31.
9. Simpkins CE, Montgomery RA, Hawxby AM, et al. Cold ischemia time and allograft outcomes in live donor renal transplantation: Is live donor organ transport feasible? Am J Transplant 2007; 7: 99.
10. Brook NR, White SA, Waller JR, etal. Non-heart beating donor kidneys with delayed graft function have superior graft survival compared with conventional heart-beating donor kidneys that develop delayed graft function. Am J Transplant 2003; 3: 614.
11. Van Loo AA, Vanholder RC, Bernaert PR, et al. Pretransplantation hemodialysis strategy influences early renal graft function. J Am Soc Nephrol 1998; 9: 473.
12. Van Biesen W, Veys N, Vanholder R, et al. The impact of the pre-transplant renal replacement modality on outcome after cadaveric kidney transplantation: The Ghent experience. Contrib Nephrol 2006; 150: 254.
13. Hörl WH. Hemodialysis membranes: Interleukins, biocompatibility, and middle molecules. J Am Soc Nephrol 2002; 13(suppl 1): S62.
14. Böhler J, Schollmeyer P, Dressel B, et al. Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: Dissociation of complement activation and neutropenia from neutro-phil degranulation. J Am Soc Nephrol 1996; 7: 234.
15. Bos JC, Grooteman MP, van Houte AJ, et al. Low polymorphonuclear cell degranulation during citrate anticoagulation: A comparison between citrate and heparin dialysis. Nephrol Dial Transplant 1997; 12: 1387.
16. Gabutti L, Ferrari N, Mombelli G, et al. The favorable effect of regional citrate anticoagulation on interleukin-1beta release is dissociated from both coagulation and complement activation. J Nephrol 2004; 17: 819.
17. Gritters M, Grooteman MP, Schoorl M, et al. Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Nephrol Dial Transplant 2006; 21: 153.
18. Lorenz M, Regele H, Schillinger M, et al. Peritransplant immunoad-sorption: A strategy enabling transplantation in highly sensitized cross-match-positive cadaveric kidney allograft recipients. Transplantation 2005; 79: 696.
19. Stevens LA, Coresh J, Greene T, et al. Assessing kidney function-Measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473.
20. Rule AD, Larson TS, Bergstralh EJ, et al. Using serum creatinine to estimate glomerular filtration rate: Accuracy in good health and in chronic kidney disease. Ann Intern Med 2004; 141: 929.
21. Yarlagadda SG, Coca SG, Garg AX, et al. Marked variation in the definition and diagnosis of delayed graft function: A systematic review. Nephrol Dial Transplant 2008; 23: 2995.
22. Humar A, Ramcharan T, Kandaswamy R, et al. Risk factors for slow graft function after kidney transplants: A multivariate analysis. Clin Transplant 2002; 16: 425.
23. Böhmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: A specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13: 1091.
24. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
25. Boros P, Bromberg JS. New cellular and molecular immune pathways in ischemia/reperfusion injury. Am J Transplant 2006; 6: 652.
26. Craddock PR, Fehr J, Dalmasso AP, et al. Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 1977; 59: 879.
27. Hakim RM, Breillatt J, Lazarus JM, et al. Complement activation and hypersensitivity reactions to dialysis membranes. N Engl J Med 1984; 311: 878.
28. Schulman G, Fogo A, Gung A, et al. Complement activation retards resolution of acute ischemic renal failure in the rat. Kidney Int1991; 40: 1069.
29. Himmelfarb J, Ault KA, Holbrook D, et al. Intradialytic granulocyte reactive oxygen species production: Aprospective, crossover trial.J Am Soc Nephrol 1993; 4: 178.
30. Combe C, Pourtein M, de Precigout V, et al. Granulocyte activation and adhesion molecules during hemodialysis with cuprophane and a high-flux biocompatible membrane. Am J Kidney Dis 1994; 24: 437.
31. Rosenkranz AR, Templ E, Traindl O, et al. Reactive oxygen product formationby human neutrophils asan early marker for biocompatibil-ity of dialysis membranes. Clin Exp Immunol 1994; 98: 300.
32. Jaber BL, Cendoroglo M, Balakrishnan VS, et al. Impact of dialyzer membrane selection on cellular responses in acute renal failure: A crossover study. Kidney Int 2000; 57: 2107.
33. Himmelfarb J, Zaoui P, Hakim R. Modulation of granulocyte LAM-1 and MAC-1 during dialysis-A prospective, randomized controlled trial. Kidney Int 1992; 41: 388.
34. Wilflingseder J, Perco P, Kainz A, et al. Biocompatibility of haemodi-alysis membranes determinedby gene expressionof human leucocytes: A crossover study. Eur J Clin Invest 2008; 38: 918.
35. Schiffl H, Lang SM, Konig A, et al. Biocompatible membranes in acute renal failure: Prospective case-controlled study. Lancet 1994; 344: 570.
36. Himmelfarb J, Tolkoff Rubin N, Chandran P, etal. A multicenter comparison of dialysis membranes in the treatment of acute renal failure requiring dialysis. J Am Soc Nephrol 1998; 9: 257.
37. Jorres A, Gahl GM, Dobis C, et al. Haemodialysis-membrane biocom-patibility and mortality of patients with dialysis-dependent acute renal failure: A prospective randomised multicentre trial. International Mul-ticentre Study Group. Lancet 1999; 354: 1337.
38. Valeri A, Radhakrishnan J, Ryan R, et al. Biocompatible dialysis membranes and acute renal failure: A study in post-operative acute tubular necrosis in cadaveric renal transplant recipients. Clin Nephrol 1996; 46: 402.
39. Romao JE Jr, Abensur H, de Castro MC, et al. Effect of dialyser bio-compatibility on recovery from acute renal failure after cadaver renal transplantation. Nephrol Dial Transplant 1999; 14: 709.
40. Dhondt A, Vanholder R, Tielemans C, et al. Effect of regional citrate anticoagulation on leukopenia, complement activation, and expression of leukocyte surface molecules during hemodialysis with unmodified cellulose membranes. Nephron 2000; 85: 334.
41. Opatrny K, Richtrova P, Polanska K, et al. Citrate anticoagulation control by ionized calcium levels does not prevent hemostasis and complement activation during hemodialysis. Artif Organs 2007; 31: 200.
42. Rosenthal JT, Danovitch GM, Wilkinson A, et al. The high cost of delayed graft function in cadaveric renal transplantation. Transplantation 1991; 51: 1115.
43. Irish WD, McCollum DA, Tesi RJ, et al. Nomogram for predicting the likelihood of delayed graft function in adult cadaveric renal transplant recipients. J Am Soc Nephrol 2003; 14: 2967.